IMpower030 Shows 28-Month EFS Gain With Perioperative Atezolizumab in Stage II-IIIB NSCLC

The phase III trial enrolled 453 patients and randomized them to four cycles of neoadjuvant platinum-based chemotherapy with or without atezolizumab, followed by surgery and up to 16 cycles of adjuvant atezolizumab or placebo. Primary endpoint was investigator-assessed event-free survival; secondary endpoints included independent review facility EFS, pathological complete response, major pathological response, and overall survival. Pathological complete response reached 29.6 percent versus 8.5 percent and major pathological response 53.6 percent versus 24.4 percent. Surgical cancellation rates stayed low and comparable across arms with no new safety signals.

Although the trial missed its prespecified statistical significance threshold for EFS, clinically meaningful separation persisted across multiple endpoints including disease-free and overall survival. These data align with CheckMate 816 and AEGEAN results, suggesting perioperative PD-L1 or PD-1 blockade improves outcomes when added to chemotherapy in resectable NSCLC. The pattern indicates that early immune engagement may reduce micrometastatic burden before and after resection.

Next steps include mature overall survival data and biomarker analyses to identify patients most likely to benefit. Regulatory submissions are anticipated once survival curves stabilize. Ongoing trials will test whether shorter adjuvant durations or ctDNA-guided de-escalation can maintain efficacy while reducing toxicity.

Evidence remains preliminary until peer-reviewed publication and longer follow-up confirm overall survival benefit.